首页> 美国卫生研究院文献>Scientific Reports >Prognostic significance of miR-122 expression after curative resection in patients with hepatocellular carcinoma
【2h】

Prognostic significance of miR-122 expression after curative resection in patients with hepatocellular carcinoma

机译:肝细胞癌根治性切除术后miR-122表达的预后意义

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Downregulation of MicroRNA-122 (miR-122) and its association with cancer progression have been reported in hepatocellular carcinoma (HCC) cell line models and a limited number of HCC samples. Recently, restoration of miR-122 expression by direct delivery of miR-122 yielded promising results in HCCs. However, the prognostic effect of miR-122 expression in human HCC samples is not fully understood. We investigated the expression level of miR-122 by quantitative real-time polymerase chain reaction in 289 curatively resected HCC samples and 20 normal liver samples and evaluated the prognostic effect of miR-122 expression. The relative quantification value of miR-122 was much lower in HCC samples than in normal liver tissues. During a median 119 months of follow-up for survival, the low miR-122 expression group showed shorter recurrence-free survival (RFS) (p = 0.033) and intrahepatic recurrence-free survival (IHRFS) (p = 0.014), and a trend of short distant metastasis-free survival (DMFS) (p = 0.149) than high expression group. On multivariate analysis, miR-122 expression was an independent prognostic factor for RFS, IHRFS and DMFS. Downregulation of miR-122 expression, frequently found in HCC samples, was an independent prognostic factor for RFS after curative resection. Emerging therapeutic approaches targeting miR-122 could be applicable in patients with miR-122 downregulated hepatocellular carcinoma.
机译:在肝细胞癌(HCC)细胞系模型和有限数量的HCC样品中,已经报道了MicroRNA-122(miR-122)的下调及其与癌症进展的关系。近来,通过直接递送miR-122恢复miR-122表达在肝癌中产生了有希望的结果。但是,尚未完全了解人肝癌样本中miR-122表达的预后效果。我们通过定量实时聚合酶链反应在289例切除的HCC样本和20例正常肝样本中调查了miR-122的表达水平,并评估了miR-122的预后。 HCC样品中miR-122的相对定量值比正常肝组织中的低得多。在中位生存期119个月的随访中,低miR-122表达组显示了更短的无复发生存期(RFS)(p = 0.033)和肝内无复发生存期(IHRFS)(p = 0.014),并且高表达组的近距离无转移生存(DMFS)趋势(p = 0.149)。在多变量分析中,miR-122表达是RFS,IHRFS和DMFS的独立预后因素。在肝癌样本中经常发现的miR-122表达下调是根治性切除术后RFS的独立预后因素。针对miR-122的新兴治疗方法可能适用于miR-122下调的肝细胞癌患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号